Wells Fargo raised the firm's price target on Argenx to $1,291 from $1,260 and keeps an Overweight rating on the shares. The firm remains constructive into Vyvgart's Phase 3 myositis read out and believes the current setup offers attractive risk/reward, with incremental analysis supporting its view that positive data could reinforce Argenx's path to becoming a large-cap biotech.
